LifeMD, Inc. (NASDAQ:LFMD) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• LifeMD has a “Moderate Buy” consensus rating from 10 brokerages, with eight buy ratings and two sell ratings. The average 12-month price target is $7.57, though several analysts recently lowered their targets.
• Shares opened at $3.46, well below the consensus target, with a 52-week range of $2.56 to $7.32. The company reported a quarterly loss of $0.16 per share and revenue of $47.28 million, both slightly below analyst expectations.
• Institutional investors increased their positions in LifeMD, and institutions and hedge funds now own 35.52% of the stock. Analysts expect the company to post a full-year loss of approximately $0.37 per share.

Shares of LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the ten brokerages that are currently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation and eight have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $7.5714.

LFMD has been the topic of several recent analyst reports. Lake Street Capital set a $5.00 price objective on shares of LifeMD in a report on Thursday, August 6th. Wall Street Zen cut shares of LifeMD from a "hold" rating to a "sell" rating in a research note on Saturday, July 18th. HC Wainwright reduced their price target on shares of LifeMD from $10.00 to $9.00 and set a "buy" rating for the company in a research report on Friday, August 7th. B. Riley Financial decreased their price target on shares of LifeMD from $10.00 to $8.00 and set a "buy" rating on the stock in a research note on Thursday, August 6th. Finally, Zacks Research cut LifeMD from a "hold" rating to a "strong sell" rating in a report on Friday, July 17th.

LifeMD Price Performance

Shares of LifeMD stock opened at $3.46 on Friday. The stock has a market cap of $166.77 million, a PE ratio of -69.19 and a beta of 2.02. The firm has a fifty day moving average price of $4.29 and a 200 day moving average price of $3.97. LifeMD has a 1 year low of $2.56 and a 1 year high of $7.32.

LifeMD (NASDAQ:LFMD - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.01). LifeMD had a net margin of 0.10% and a negative return on equity of 168.23%. The business had revenue of $47.28 million during the quarter, compared to analysts' expectations of $49.16 million. As a group, equities analysts expect that LifeMD will post -0.37 EPS for the current year.

Institutional Trading of LifeMD

A number of institutional investors have recently made changes to their positions in LFMD. Federated Hermes Inc. increased its position in shares of LifeMD by 278.1% during the fourth quarter. Federated Hermes Inc. now owns 980,285 shares of the company's stock worth $3,343,000 after purchasing an additional 721,018 shares in the last quarter. Prescott Group Capital Management L.L.C. purchased a new position in LifeMD in the 4th quarter valued at $2,344,000. Arrowstreet Capital Limited Partnership boosted its stake in LifeMD by 1,767.8% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 434,937 shares of the company's stock worth $5,924,000 after purchasing an additional 411,651 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in LifeMD by 581.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 412,571 shares of the company's stock worth $5,619,000 after purchasing an additional 352,004 shares during the last quarter. Finally, Whetstone Capital Advisors LLC grew its holdings in shares of LifeMD by 89.6% during the fourth quarter. Whetstone Capital Advisors LLC now owns 703,053 shares of the company's stock worth $2,397,000 after buying an additional 332,269 shares in the last quarter. 35.52% of the stock is owned by institutional investors and hedge funds.

LifeMD Company Profile

LifeMD NASDAQ: LFMD is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source